Rafael (RFL) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
16 Dec, 2025Company overview and business model
Incorporated in Delaware with principal executive offices in Newark, NJ; operates as a holding company.
Management team and governance
William Conkling serves as Chief Executive Officer and principal executive officer.
Howard S. Jonas is Chairman of the Board; Susan Y. Bernstein is Chief Financial Officer.
Board includes directors with diverse backgrounds, including Dr. Mark Stein and Dr. Michael J. Weiss.
Offering details and pricing
Registration statement filed on Form S-3 for a shelf offering, allowing securities to be sold from time to time after effectiveness.
Estimated total expenses for issuance and distribution are $19,327.50, including SEC, legal, accounting, and printing fees.
Securities may be offered on a delayed or continuous basis under Rule 415.
Latest events from Rafael
- Net loss widened on higher R&D, cash at $37.8M, pivotal trial results due Q3.RFL
Q2 202616 Mar 2026 - $25M shelf offering to fund rare disease drug development and strategic initiatives.RFL
Registration Filing16 Dec 2025 - Net loss rose to $9.8M on higher R&D costs, with $45.5M in cash and Phase 3 trial ongoing.RFL
Q1 202612 Dec 2025 - Annual meeting to elect directors, ratify auditor, and expand equity plan by 750,000 shares.RFL
Proxy Filing1 Dec 2025 - Annual meeting to elect directors, ratify auditor, and expand equity plan share pool.RFL
Proxy Filing18 Nov 2025 - Phase 3 trial progress and $25M rights offering drive improved financial outlook.RFL
Q4 202529 Oct 2025 - Q1 FY2025 net loss rose to $9.0M as focus shifts to Trappsol Cyclo™ post-merger.RFL
Q1 202513 Jun 2025 - FY2024 net loss reached $34.4M, with a major IPR&D charge and focus shifting to the Cyclo merger.RFL
Q4 202413 Jun 2025 - Net loss narrowed, cash strengthened, and pivotal Phase 3 trial results are imminent.RFL
Q3 202511 Jun 2025